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levels of inflammatory cytokines or serum uric acid or their changes. Serum uric acid and
its changes independently predict poor prognosis in CHF, more acurately than do plasma
cytokines.
1163-120 Complement Activation in Patients With Congestive 
Heart Failure
Suhua Wu, Hong Ma, Yugang Dong, Jiangui He, Huiying Ye, Yujun Zhong, First Affiliated 
Hospital, Sun Yet-Sen University, Guangzhou, People's Republic of China
Background Increasing evidence suggests that complement may play a role in the
pathogenesis of myocardial damage secondary to ischemia and reperfusion, but the role
of complement in congestive heart failure is at present unclear. Objectives To determine
whether the complement system is activated and its relationship to clinical outcomes in
patients with congestive heart failure (CHF). Methods The plasma levels of products of
complement activation C4d (classic pathway), Bb (alternative pathway), 3bc (final com-
mon pathway) and C5b-9 (terminal complement complex) were measured by enzyme-
linked immunosorbent assay(ELISA) method in forty-four patients with CHF and sixteen
normal age and sex matched volunteers. The left ventricular ejection fractions of all
patients were measured by electron beam computed tomography (EBCT). Forty-one
patients with CHF were followed up for 13±3 months to determine the combined clinical
outcomes (hospitalization with worsening heart failure or death). Results Our major find-
ing were (1) The plasma levels of C4d, Bb, C3bc and C5b-9 in patients with CHF were
significantly higher than those in normal volunteers. (2) Significantly more of the patients
with highest levels of C5b-9 ( highest 50th percentile ) had worse left ventricular function
and adverse clinical outcomes compared with the patients with lowest levels of C5b-9 (
lowest 50th percentile). Conclusions We have observed an activation of complement
system and an association between high levels of C5b-9 and adverse clinical events in
patients with CHF. Our findings suggested that complement might be added to the list of
possible therapeutic targets.
1163-121 Prognostic Role of Neutrophil and Lymphocyte Counts 
in Heart Failure: Results From Val-HeFT
Inder S. Anand, Joseph Yen, Viorel G. Florea, Allen Hester, Robert Glazer, Roberto 
Latini, Aldo Maggioni, Jay N. Cohn, Veterans Affairs Medical Center and University of 
Minnesota, Minneapolis, MN
Background. Lymphocyte and neutrophil counts predict cardiovascular events in patients
with coronary artery disease. Their role in heart failure (HF), however, is not known. We
evaluated the prognostic value of baseline (BL) neutrophil and lymphocyte counts on
mortality and first morbid event (M&M;) in the Valsartan Heart Failure Trial (Val-HeFT).
Methods and Results. Blood counts were measured at BL and during follow-up. Cox pro-
portional hazards analysis was made for all cause mortality and M&M; with BL neutrophil
and lymphocyte counts, classified by median and quartile (Q) groupings and used as
independent variables in separate analyses. Patients with high BL neutrophil counts and
low BL lymphocyte counts had more advanced HF. Both neutrophil and lymphocyte
counts were significant multivariate predictors of mortality and M&M; when analyzed as
continuous, dichotomized or Q variables. Whereas, higher neutrophil count was associ-
ated with greater mortality and M&M;, higher BL lymphocyte count was associated with a
lower mortality and M&M;. Relative risk (RR) for neutrophils was 1.315 (95% CI 1.172 –
1.458; p=0.00016) and for lymphocytes 0.789 (95% CI 0.644 – 0.934, p=0.00131). Com-
parison of RRs and 95 % CIs with other dichotomized (> vs < median) multivariate pre-
dictors of mortality in descending order of p-value is shown in Table.
Conclusions: High BL neutrophil and low BL lymphocyte counts are important predictors
of outcomes in HF, suggesting a possible role of inflammation in the progression of HF.
1163-122 Does Wider QRS Reflect Heart Failure Severity?
Teresa De Marco, Michael B. Higginbotham, Leslie A. Saxon, Sudha Balasubramanian, 
Patrick Yong, Elyse Foster, University of California San Francisco, San Francisco, CA, 
Guidant Corporation, St. Paul, MN
Background: A wide QRS is used as a surrogate measure of ventricular dysynchrony for
selecting cardiac resynchronization therapy candidates. It is not clear if prolonged QRS
correlates with other baseline measures such as left ventricular structure, systolic func-
tion, exercise tolerance, and heart failure symptoms.
Methods: Patients participating in the VENTAK® CHF/CONTAK® CD Biventricular Pac-
ing Study were included in this retrospective analysis. Correlation of baseline QRS was
calculated for each of the following baseline parameters: left ventricular ejection fraction
(LVEF), LV internal dimension, systole (LVIDs), peak oxygen consumption (peak VO2),
six-minute walk distance (6MWD), quality of life (QOL; Minnesota living with heart failure
questionnaire) and NYHA class.
Results: At implant the study population consisted of 83% males, mean age 66 ± 10
years, NYHA II (33%), III (58%), IV (9%), mean LVEF 21±7%, mean QRS width 158 ± 28
ms. Baseline QRS significantly correlated with baseline LVEF, LVIDs, peak VO2, 6MWD
but not with QOL and NYHA Class.
Conclusions: Widening of the QRS is significantly associated with measures of heart
failure severity including greater LV dimension, lower LVEF and reduced exercise toler-
ance but does not correlate with measures of symptomatic status. If these findings can
be confirmed, then the degree of QRS prolongation in heart failure patients may serve as
an inexpensive and reliable surrogate indicator of these measures of heart failure sever-
ity.
1163-123 Relationship Between Plasma C-Reactive Protein 
Concentration on Admission and Long-Term Outcome 
in Unselected Hospitalized Heart Failure Patients
Colin Berry, Karen Hogg, Karen Stevenson, John Norrie, John J. McMurray, University of 
Glasgow, Glasgow, United Kingdom
Background: Although systemic inflammation is recognised in heart failure (HF) its impor-
tance in relation to outcome is uncertain. Plasma c-reactive protein (pCRP) concentration
is typically elevated in inflammatory conditions and is recognised as a marker of systemic
inflammation.
Methods: We studied all index emergency admissions with HF to one University hospital
(which provides exclusive acute medical care to the local urban district) during the year
2000. Echocardiography was undertaken by a single operator. Reduced LVSF was
defined as an ejection fraction of <40%. Hematological and biochemical data (from the
initial blood samples taken on the day of admission) were obtained from hospital elec-
tronic records. Information on death was obtained from the national record linkage data-
base for all patients.
Results: 528 consecutive first admissions with HF were identified. The median follow-up
was 693 days (range 1 - 978 days). Median (interquartile range) pCRP concentration was
16 (5, 183) mg/L, and 65% of patients had an elevated (> 10 mg/L) pCRP concentration.
45% and 35% of patients had a pCRP concentration greater than 20 and 30 mg/L,
respectively. Univariate predictors of an elevated pCRP concentration included hemoglo-
bin, hematocrit, white cell count (WCC), platelet count, serum creatinine concentration
and plasma fibrinogen, sodium and albumin concentrations. On multivariate analysis,
predictors (odds ratio, 95% CI) of pCRP concentration included WCC (1.9 [1.4, 2.9]),
fibrinogen count (1.9 [1.3, 2.6]), and albumin (0.7 [0.5, 0.9]). pCRP concentration was an
independent predictor of in-hospital survival (Cox proportional hazard ratio (HR) 0.2 per
SD (61 mg/L); 95% CI 0.1,0.6, P=0.001), and long-term mortality (CRP per SD, HR 1.4;
95% CI 1.2 -1.7; P <0.001 ).
Conclusion: Systemic inflammation, indicated by an elevated pCRP concentration, is
very common in hospitalized HF patients, and predicts long-term adverse outcome. That
CRP is an independent predictor of mortality suggests that this protein may have harmful
effects.
1163-124 Improvement in Autonomic Dysfunction Manifested by 
Altered Heart Rate Variability, T-Wave-Alternans and 
Norepinephrine by Long-Term Exercise in Chronic Heart 
Failure
Robert M. Nechwatal, Michael Horn, Uwe Scharf, Bettina Mochalski, Ulrike 
Lachenmeyer, Christiaan Barnard Klinik, Dahlen, Germany
Background: In recent years exercise training has become an established therapy for
patients with stable chronic heart failure. However there is a paucity of data on the effects
of long term training on autonomic dysfunction. Methods: 100 patients with DCM and
CHD were randomized to an exercise (n=50, mean age:49,9+-9,3,mean ejection fraction
(EF) 33,3+-5,7%)or to a control group (n=50, mean age:54,7+-11,3,EF: 32,4+-
5,3%).Patients underwent six 20 minute supervised training sessions per week at a VO2
of 60% VO2peak. Before and after the six month study period exercise testing with respi-
ratory gas exchange, heart rate variability in the time domain on holter monitoring, nore-
pinephrine plasma values and T-wave alternans testing were performed. Results:See
Table.VO2AT: oxygen uptake at the anaerobic threshold. *: p<0,05 **: p<0,01 vs pre-
training.id: indeterminate. 10 patients in the exercise group and 2 in the control group did
not complete the protocol: one of each group died unassociated with exercise, one of
Table (for changes over time between drugs: all p>0.2)
Time point TNF sTNFR1 IL-6 IL1-RA Uric Acid
(pg/mL) (pg/mL) (pg/mL) (pg/mL) (mg/dL)
Carvedilol-BL 2.20±0.14 1575±79 3.25±0.30 400±25 7.26±0.24
Carvedilol-FU 2.13±0.22 1615±72 3.53±0.32 406±27 7.47±0.23
Placebo-BL 1.92±0.11 1589±59 3.26±0.25 410±39 7.24±0.23
Placebo-FU 1.96±0.26 1621±80 3.84±0.32 409±30 7.11±0.25
Variable BNP NYHA, III 
and IV
LVIDD/
BSA
Uric 
Acid
Neutrop
hils
Plasma 
Renin 
Activity
Beta 
Blocke
r Use
Lympho
cytes
Norepin
ephrine
Age, 
>65 yrs
Ischem
ic 
etiolog
y
Creatini
ne
Relative 
Risk
1.906 1.398 1.354 1.357 1.315 1.324 0.754 0.789 1.272 1.260 1.208 1.206
95% CI 1.748, 
2.065
1.257, 
1.539
1.211, 
1.497
1.206, 
1.508
1.172, 
1.458
1.177, 
1.471
0.597, 
0.910
0.644, 
0.934
1.125, 
1.419
1.113, 
1.407
1.059, 
1.357
1.053, 
1.358
p-Value <0.00001 <0.00001 0.00003 0.00007 0.00016 0.00018 0.0004 0.00131 0.00132 0.00216 0.0123 0.01701
Variable
 N  Correlation  P-value
LVEF at Baseline
 500  -0.17  <0.01
LVIDs at Baseline
 420  0.27  <0.01
Peak VO2 at Baseline
 382  -0.11  0.03
6 MWD at Baseline
 438  -0.12  0.02
QOL at Baseline
 457  0.03  0.59
NYHA at Baseline
 465  0.08  0.10
